| 
Results for longacting. Search took 0.02 seconds.
Once-weekly Exenatide Long-acting Release (LAR) Injection Found Superior Over Twice-Daily BYETTA® (exenatide) Injection
in Daily Diabetic, on November 6, 2007
Positive results of a comparator study of once-weekly exenatide long-acting release (LAR) injection and byetta ® (exenatide) injection taken twice daily in patients with type 2 diabetes have recently been announced by Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. ...